Published in J Neurol on October 27, 2013
Screening of dementia genes by whole-exome sequencing in early-onset Alzheimer disease: input and lessons. Eur J Hum Genet (2015) 0.89
A diagnostic scale for Alzheimer's disease based on cerebrospinal fluid biomarker profiles. Alzheimers Res Ther (2014) 0.86
Cerebrospinal fluid amyloid-β 42/40 ratio in clinical setting of memory centers: a multicentric study. Alzheimers Res Ther (2015) 0.86
Pro-Apoptotic Kinase Levels in Cerebrospinal Fluid as Potential Future Biomarkers in Alzheimer's Disease. Front Neurol (2015) 0.82
The screening of Alzheimer's patients with CSF biomarkers, modulates the distribution of APOE genotype: impact on clinical trials. J Neurol (2014) 0.82
Conflicting cerebrospinal fluid biomarkers and progression to dementia due to Alzheimer's disease. Alzheimers Res Ther (2016) 0.76
Utility of CSF biomarkers in psychiatric disorders: a national multicentre prospective study. Alzheimers Res Ther (2016) 0.75
The pre-synaptic vesicle protein synaptotagmin is a novel biomarker for Alzheimer's disease. Alzheimers Res Ther (2016) 0.75
The influence of cerebrospinal fluid (CSF) biomarkers on clinical dementia evaluations. Alzheimers Dement (2014) 0.75
Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology (1984) 119.59
The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 24.26
Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 24.02
The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 21.80
Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology (2001) 7.51
Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization. Neurology (2009) 7.04
Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol (2010) 6.55
11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol (2010) 5.03
Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005-2010. J Neuropathol Exp Neurol (2012) 3.46
Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol (2009) 3.34
CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology (2003) 3.18
Clinico-neuropathological correlation of Alzheimer's disease in a community-based case series. J Am Geriatr Soc (1999) 2.63
CSF biomarkers in frontotemporal lobar degeneration with known pathology. Neurology (2008) 2.43
The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. Alzheimers Dement (2011) 1.87
Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort. Neurology (2011) 1.56
Clinical criteria for the diagnosis of Alzheimer disease: still good after all these years. Am J Geriatr Psychiatry (2008) 1.39
Potential impact of amyloid imaging on diagnosis and intended management in patients with progressive cognitive decline. Alzheimer Dis Assoc Disord (2013) 1.28
Quantifying the added value of a diagnostic test or marker. Clin Chem (2012) 1.28
The paradox of syndromic diversity in Alzheimer disease. Nat Rev Neurol (2012) 1.18
Early onset Alzheimer's disease is associated with a distinct neuropsychological profile. J Alzheimers Dis (2012) 1.11
Diagnostic impact of CSF biomarkers in a local hospital memory clinic. Dement Geriatr Cogn Disord (2010) 1.03
Impact of the 2008-2012 French Alzheimer Plan on the use of cerebrospinal fluid biomarkers in research memory center: the PLM Study. J Alzheimers Dis (2013) 1.00
Intersite variability of CSF Alzheimer's disease biomarkers in clinical setting. Alzheimers Dement (2012) 0.99
The primary care diagnosis of dementia in Europe: an analysis using multidisciplinary, multinational expert groups. Aging Ment Health (2008) 0.94
Amyloid-β oligomers in cerebrospinal fluid are associated with cognitive decline in patients with Alzheimer's disease. J Alzheimers Dis (2012) 0.91
Impact of diagnostic disclosure in dementia on patients and carers: qualitative case series analysis. Aging Ment Health (2006) 0.86
Lessons from Multicenter Studies on CSF Biomarkers for Alzheimer's Disease. Int J Alzheimers Dis (2010) 0.86
The 2008-2012 French Alzheimer plan: description of the national Alzheimer information system. J Alzheimers Dis (2012) 0.86
CSF biomarkers for Alzheimer's pathology and the effect size of APOE ɛ4. Mol Psychiatry (2013) 0.84
Alzheimer disease biomarker testing in cerebrospinal fluid: a method to harmonize assay platforms in the absence of an absolute reference standard. Clin Chem (2013) 0.82
Exacerbated CSF abnormalities in younger patients with Alzheimer's disease. Neurobiol Dis (2013) 0.81
Cerebrospinal fluid biomarker results in relation to neuropathological dementia diagnoses. Alzheimers Dement (2010) 0.81
[Multicenter study on lumbar puncture indication, clinical practice and feasibility]. Rev Neurol (Paris) (2011) 0.79
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol (2007) 18.62
Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet (2009) 14.86
Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain (2011) 9.90
Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet (2011) 9.23
Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol (2010) 8.74
APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nat Genet (2005) 7.66
Recent advances in iron oxide nanocrystal technology for medical imaging. Adv Drug Deliv Rev (2006) 4.69
A meta-analysis of human embryonic stem cells transcriptome integrated into a web-based expression atlas. Stem Cells (2007) 3.62
Ambulatory system for human motion analysis using a kinematic sensor: monitoring of daily physical activity in the elderly. IEEE Trans Biomed Eng (2003) 3.21
Long-term use of standardised Ginkgo biloba extract for the prevention of Alzheimer's disease (GuidAge): a randomised placebo-controlled trial. Lancet Neurol (2012) 2.65
Mutations in the gene encoding PDGF-B cause brain calcifications in humans and mice. Nat Genet (2013) 2.62
A polymorphism in CALHM1 influences Ca2+ homeostasis, Abeta levels, and Alzheimer's disease risk. Cell (2008) 2.55
Drugs with anticholinergic properties, cognitive decline, and dementia in an elderly general population: the 3-city study. Arch Intern Med (2009) 2.41
Poststroke dementia. Lancet Neurol (2005) 2.41
TARDBP mutations in motoneuron disease with frontotemporal lobar degeneration. Ann Neurol (2009) 2.30
Relationships between hippocampal atrophy, white matter disruption, and gray matter hypometabolism in Alzheimer's disease. J Neurosci (2008) 2.15
What does transient global amnesia really mean? Review of the literature and thorough study of 142 cases. Brain (2006) 2.05
Mutation of the PDGFRB gene as a cause of idiopathic basal ganglia calcification. Neurology (2012) 2.05
Phenotypic spectrum of probable and genetically-confirmed idiopathic basal ganglia calcification. Brain (2013) 2.02
Management of agitation and aggression associated with Alzheimer disease. Nat Rev Neurol (2009) 1.86
SOD1, ANG, VAPB, TARDBP, and FUS mutations in familial amyotrophic lateral sclerosis: genotype-phenotype correlations. J Med Genet (2010) 1.85
Phenotype variability in progranulin mutation carriers: a clinical, neuropsychological, imaging and genetic study. Brain (2008) 1.84
Phenotype associated with APP duplication in five families. Brain (2006) 1.83
Abnormal retinal thickness in patients with mild cognitive impairment and Alzheimer's disease. Neurosci Lett (2007) 1.80
Treatment of anterior communicating artery aneurysms: complementary aspects of microsurgical and endovascular procedures. J Neurosurg (2003) 1.79
CNTF promotes survival of retinal ganglion cells after induction of ocular hypertension in rats: the possible involvement of STAT3 pathway. Eur J Neurosci (2004) 1.77
Mutations in SPG11 are frequent in autosomal recessive spastic paraplegia with thin corpus callosum, cognitive decline and lower motor neuron degeneration. Brain (2007) 1.76
Atlastin1 mutations are frequent in young-onset autosomal dominant spastic paraplegia. Arch Neurol (2004) 1.72
Dissociating atrophy and hypometabolism impact on episodic memory in mild cognitive impairment. Brain (2003) 1.72
Progranulin null mutations in both sporadic and familial frontotemporal dementia. Hum Mutat (2007) 1.69
Macrophage activity in infected areas of an experimental vertebral osteomyelitis model: USPIO-enhanced MR imaging--feasibility study. Radiology (2008) 1.67
Implication of the immune system in Alzheimer's disease: evidence from genome-wide pathway analysis. J Alzheimers Dis (2010) 1.65
Evaluation of the Two-Way Communication Checklist as a clinical intervention. Results of a multinational, randomised controlled trial. Br J Psychiatry (2004) 1.61
Quality of life and brain damage after microsurgical clip occlusion or endovascular coil embolization for ruptured anterior communicating artery aneurysms: neuropsychological assessment. J Neurosurg (2009) 1.61
Macrophage imaging by USPIO-enhanced MR for the differentiation of infectious osteomyelitis and aseptic vertebral inflammation. Eur Radiol (2009) 1.58
Septic arthritis: monitoring with USPIO-enhanced macrophage MR imaging. Radiology (2011) 1.57
TREM2 R47H variant as a risk factor for early-onset Alzheimer's disease. J Alzheimers Dis (2013) 1.57
Phosphorylation of eukaryotic initiation factor-2alpha (eIF2alpha) is associated with neuronal degeneration in Alzheimer's disease. Neuroreport (2002) 1.55
Novelty seekers and impulsive subjects are low in morningness. Eur Psychiatry (2004) 1.55
Working memory and executive functions in transient global amnesia. Brain (2003) 1.53
The significance of cortical cerebellar microbleeds and microinfarcts in neurodegenerative and cerebrovascular diseases. A post-mortem 7.0-tesla magnetic resonance study with neuropathological correlates. Cerebrovasc Dis (2015) 1.53
PNPLA6 mutations cause Boucher-Neuhauser and Gordon Holmes syndromes as part of a broad neurodegenerative spectrum. Brain (2013) 1.51
Long-term follow-up of acute partial transverse myelitis. Arch Neurol (2012) 1.50
Involvement of hyperprolinemia in cognitive and psychiatric features of the 22q11 deletion syndrome. Hum Mol Genet (2006) 1.50
Longitudinal brain metabolic changes from amnestic mild cognitive impairment to Alzheimer's disease. Brain (2009) 1.50
FDG-PET measurement is more accurate than neuropsychological assessments to predict global cognitive deterioration in patients with mild cognitive impairment. Neurocase (2005) 1.49
Evidence for a role of the rare p.A152T variant in MAPT in increasing the risk for FTD-spectrum and Alzheimer's diseases. Hum Mol Genet (2012) 1.46
Improved MR coronary angiography with use of a new rapid clearance blood pool contrast agent in pigs. Radiology (2003) 1.43
Treatment of vascular risk factors is associated with slower decline in Alzheimer disease. Neurology (2009) 1.43
C9orf72 repeat expansions are a rare genetic cause of parkinsonism. Brain (2013) 1.42
Patient and caregiver perspectives of quality of life in dementia. An investigation of the relationship to behavioural and psychological symptoms in dementia. Dement Geriatr Cogn Disord (2008) 1.41
Management of behavioral problems in Alzheimer's disease. Int Psychogeriatr (2010) 1.38
mTOR/p70S6k signalling alteration by Abeta exposure as well as in APP-PS1 transgenic models and in patients with Alzheimer's disease. J Neurochem (2005) 1.34
The National Dementia strategy in England. BMJ (2009) 1.31
mTOR-dependent signalling in Alzheimer's disease. J Cell Mol Med (2008) 1.29
Mutation analysis and association studies of the ubiquitin carboxy-terminal hydrolase L1 gene in Huntington's disease. Neurosci Lett (2002) 1.28
REEP1 mutations in SPG31: frequency, mutational spectrum, and potential association with mitochondrial morpho-functional dysfunction. Hum Mutat (2011) 1.26
Magnetic resonance imaging of experimental atherosclerotic plaque: comparison of two ultrasmall superparamagnetic particles of iron oxide. J Magn Reson Imaging (2006) 1.23
Dysexecutive syndrome: diagnostic criteria and validation study. Ann Neurol (2010) 1.22
Hepatitis C virus controls interferon production through PKR activation. PLoS One (2010) 1.21
Dynamic study of blood-brain barrier closure after its disruption using ultrasound: a quantitative analysis. J Cereb Blood Flow Metab (2012) 1.21
Diagnostic criteria for vascular cognitive disorders: a VASCOG statement. Alzheimer Dis Assoc Disord (2014) 1.21
Biochemistry of Tau in Alzheimer's disease and related neurological disorders. Expert Rev Proteomics (2008) 1.21
Cell type-specific localization of human cardiac S1P receptors. J Histochem Cytochem (2002) 1.20
Wavelength modulation spectroscopy: combined frequency and intensity laser modulation. Appl Opt (2003) 1.20
Mutations other than null mutations producing a pathogenic loss of progranulin in frontotemporal dementia. Hum Mutat (2007) 1.20
Anatomical and functional alterations in semantic dementia: a voxel-based MRI and PET study. Neurobiol Aging (2006) 1.20
The CALHM1 P86L polymorphism is a genetic modifier of age at onset in Alzheimer's disease: a meta-analysis study. J Alzheimers Dis (2010) 1.19
New model for analysis of dynamic contrast-enhanced MRI data distinguishes metastatic from nonmetastatic transplanted rodent prostate tumors. Magn Reson Med (2004) 1.18
Subcortical hyperintensities are associated with cognitive decline in patients with mild cognitive impairment. Stroke (2007) 1.18
Should older adults be screened for dementia? Alzheimers Dement (2006) 1.17
C9ORF72 repeat expansions in the frontotemporal dementias spectrum of diseases: a flow-chart for genetic testing. J Alzheimers Dis (2013) 1.16
Frontotemporal dementia: a randomised, controlled trial with trazodone. Dement Geriatr Cogn Disord (2004) 1.15
An inverse agonist of the histamine H(3) receptor improves wakefulness in narcolepsy: studies in orexin-/- mice and patients. Neurobiol Dis (2007) 1.15
A senescence-like cell-cycle arrest occurs during megakaryocytic maturation: implications for physiological and pathological megakaryocytic proliferation. PLoS Biol (2010) 1.14
Monitoring blood-brain barrier status in a rat model of glioma receiving therapy: dual injection of low-molecular-weight and macromolecular MR contrast media. Radiology (2010) 1.13
Prevalence of small cerebral bleeds in patients with a neurodegenerative dementia: a neuropathological study. J Neurol Sci (2010) 1.13
Cerebrospinal fluid collection tubes: a critical issue for Alzheimer disease diagnosis. Clin Chem (2012) 1.11
Brain histamine and schizophrenia: potential therapeutic applications of H3-receptor inverse agonists studied with BF2.649. Biochem Pharmacol (2007) 1.11
Movement disorders and Creutzfeldt-Jakob disease: a review. Parkinsonism Relat Disord (2005) 1.11
Involvement of double-stranded RNA-dependent protein kinase and phosphorylation of eukaryotic initiation factor-2alpha in neuronal degeneration. J Neurochem (2002) 1.11
Aminopeptidase A contributes to the N-terminal truncation of amyloid beta-peptide. J Neurochem (2009) 1.10
PDGFB partial deletion: a new, rare mechanism causing brain calcification with leukoencephalopathy. J Mol Neurosci (2014) 1.10